IT Consulting & Software company Zensar Technologies announced Q1FY25 results: In Q1FY25, the company reported revenue of USD 154.4 million, sequential QoQ growth of 4.2% in reported currency and 4.3% in constant currency. On a YoY basis this translates to 3.4% growth in reported currency The company reported net cash of USD 280.9 million at the end of Q1FY25, QoQ growth of 7.3% For the second consecutive quarters we have witnessed growth across all the verticals Banking and Financial Services reported a sequential QoQ revenue growth of 6.8% in both reported and constant currency Manufacturing and Consumer Services reported a sequential QoQ revenue growth of 2.4% in reported currency and 2.7% in constant currency Telecommunication, Media and Technology reported a sequential QoQ revenue growth of 1.2% in both reported and constant currency Healthcare and Life Sciences reported a sequential QoQ revenue growth of 6.9% in both reported and constant currency US region reported a sequential QoQ revenue growth of 6.5% in reported currency and 6.6% in constant currency On July 17, 2024, Zensar has entered into definitive agreement for acquisition of 100% stake in Bridge View Life Sciences, a Pennsylvania-based technology and consulting solutions company in the Life Sciences industry. This move reinforces our focus on the Healthcare and Life Sciences vertical Manish Tandon, CEO and Managing Director, Zensar, said, “Our unwavering commitment to engineering excellence, customer experience, and client engagement helped us deliver strong results in Q1FY25. We recorded growth in overall company revenue driven by sequential growth across all our verticals. Buoyed by our strong customer experience score and with the help of key strategic investments, we continue to deepen our engagement to drive greater value for our customers, stakeholders and employees alike.” Further, commenting on the Q1FY25 performance, Manish Tandon said “Our disciplined approach on execution helped us to improve cash and cash equivalents to USD 280.9 million, QoQ addition of 19.2 million. Sequentially, we have improved our DSO by 1 day to 72 days. Our Order book stood at USD 154.0 million and PAT at 12.3% for the quarter Result PDF
Conference Call with Zensar Technologies Management and Analysts on Q1FY25 Performance and Outlook. Listen to the full earnings transcript.